TC
Thomas D. Carey

Thomas D. Carey insider trades: Standard Biotools (LAB) stock buys and sales

Standard Biotools Last trade Nov 5, 2026 26 Form 4 filings
$0
Sold, last 12 months
0 sales
$47K
Bought, last 12 months
1 buy
8
Open-market trades
since 2001
3
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Thomas reports to the SEC

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Nov 5, 2026LAB↑ Buy$47K
Jul 31, 2020EXAS↓ Sell10b5-1$2.9M
Jul 31, 2019EXAS↓ Sell10b5-1$1.2M
Feb 28, 2019EXAS↓ Sell10b5-1$720K
Jul 30, 2018EXAS↓ Sell10b5-1$202K
Apr 10, 2018EXAS↓ Sell10b5-1$336K
Aug 17, 2017EXAS↑ Buy$94K
Jun 2, 2001EXAS↓ Sell10b5-1$1.8M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other LAB insiders

Open-market trades in the last 12 months

About Thomas D. Carey's insider trades

Thomas D. Carey is an insider at Standard Biotools (LAB). Since Jun 2, 2001, Thomas has reported 2 open-market purchases worth $141K and 6 sales worth $7.1M on SEC Form 4. In the last 12 months: 1 buy ($47K).

6 sales (100% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.

Their filings also include grants and awards (17 filings), shares returned to the company (1 filing), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LAB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.